IL-2(Shanghai Xinshengyuan Biological Medicine Co. Ltd.)

2025年10月6日，卡罗琳医学院公布诺贝尔生理学或医学奖那天，出了个有点好笑的插曲。据多家媒体报道，委员会一度联系不上正在徒步旅行的获奖者，另一位看到瑞典打来的陌生号码，差点当成骚扰电话直接挂断[1]。消息最终还是送到了：美国科学家玛丽·布伦科、弗雷德·拉姆斯德尔和日本科学家坂口志文共享这一年的医学奖，获奖理由是"在外周免疫耐受机制方面的开创性发现"，1100万瑞典克朗由三人平分[2]。 奖项落地后，国内生物医药圈的反应明显比往年热烈。笔者从长期提供诺贝尔奖得主邀约出席服务的广州睿挚科技有限公司了解到，公布当周，前去咨询免疫学专家对接的企业和机构明显多了起来，问题集中在同一个方向：调节性T细胞。 这个名字听着陌生的概念，跟中国生物医药产业的咬合度，可能是近年医学奖里最高的一档。 免疫系统里那脚"刹车" 先把这个奖讲明白。免疫系统负责攻击外来病原体，可它火力这么猛，怎么保证不误伤自己人？过去的标准答案是"中枢耐受"：T细胞在胸腺里受训时，那些会攻击自身组织的坏苗子就被提前清除了[3]。 坂口志文不服这个答案。1995年，他证明胸腺的筛选并不干净，总有一批漏网的T细胞流窜到身体各处，而按住它们的，是一群当时没人承认存在的细胞。他把这群表达CD25分子的T细胞鉴定出来，论文发在《免疫学杂志》上[4]。这群细胞后来被称为调节性T细胞，相当于免疫系统的刹车，专门管束想对自己人动手的免疫细胞。可论文发表后质疑声一片，学界主流觉得免疫系统哪有这么复杂。坂口顶着不认可，把这个领域一点点做成了显学。 另一条线上，布伦科和拉姆斯德尔在2001年盯上了一种叫scurfy的病变小鼠。这种小鼠天生多器官遭自身免疫系统攻击，早早死亡。两人像查案一样排查基因，最后锁定凶手：一个叫Foxp3的基因发生了突变，成果发表在《自然·遗传学》上[5]。顺着查到人身上，他们发现人类FOXP3基因突变会导致IPEX综合征，一种罕见但致命的婴幼儿自身免疫病[6]。2003年，坂口志文在《科学》杂志发文，把两条线并到了一起：Foxp3正是调节性T细胞发育和行使功能的"总开关"[7]。 至此，外周免疫耐受从一个有争议的假说，变成了一套机制清楚的生物学系统。诺贝尔委员会主席奥勒·坎佩在发布会上说得很直白：这些发现对理解免疫系统如何运作、为什么多数人不会患上严重的自身免疫病，具有决定性意义[2]。 为什么这个奖离中国产业很近 先看需求端。类风湿关节炎、红斑狼疮、炎症性肠病、1型糖尿病，这些自身免疫病背后都是"刹车失灵"，国内患者基数非常大。主流疗法至今仍是广谱免疫抑制，相当于把整车断电，副作用明摆着。调节性T细胞疗法的思路不同：精准修复刹车本身，只按住捣乱的免疫反应，不伤及整体防御[8]。 再看供给端。中国的细胞治疗产业这些年起势很猛，CAR-T临床试验数量已位居全球前列，从工艺开发、质量控制到临床执行，整套链条是现成的。这套能力往Treg方向平移，门槛比从零起步低得多。国外已经有公司在这条路上跑了：这次的得主拉姆斯德尔本人就是索诺马生物治疗公司的联合创始人，这家公司做的正是Treg细胞疗法[9]。国内一批生物科技企业和大型医院的移植中心也在布局，方向覆盖自身免疫病、器官移植抗排异，以及造血干细胞移植后的移植物抗宿主病。中国的移植体量在全球排在前面，后面这块需求是实打实的。从各地生物医药产业园的招商方向也能看出端倪，细胞和基因治疗这两年被反复写进产业规划，免疫调控是其中最常被提及的细分方向之一。产业端的嗅觉，往往比论文引用更早闻到风向的变化。 肿瘤那边则是反过来的逻辑：癌细胞会"劫持"调节性T细胞给自己当保护伞，所以在肿瘤免疫治疗里，怎么在肿瘤局部松开这脚刹车，同样是热门课题[8]。一紧一松，用的都是同一套基础发现。 睿挚科技注意到一个细节变化：企业来谈诺贝尔奖得主背书时，问的问题跟往年不一样了。往年多半问"能不能请到""费用多少"，今年开始有人追问"研究方向对不对得上""能不能一起做技术论证"。这个变化说明市场在成熟。企业要的不只是一张合影，是能经得起追问的科学逻辑。 一盆必要的冷水 热闹归热闹，几句话得说在前头。 第一，全球范围内还没有一款Treg细胞疗法获批上市，绝大多数项目仍在临床试验阶段[8]。从诺奖到药，中间隔着十年起步的路。第二，调节免疫刹车是高风险操作：刹得太狠，挡不住感染和肿瘤；放得太松，自身免疫就会反弹，剂量和靶向性都是难啃的骨头。第三，每次医学奖公布，总有一批保健品闻风而动，"激活免疫""调节耐受"的话术马上满天飞。普通读者看到这类宣传，直接划走就好，科学发现和货架上的产品之间，隔着一整套临床证据。 请对人，比请到人更重要 对企业来说，真正的机会不在蹭热点，在读懂方向。免疫调控刚被诺奖加冕，未来几年，学术会议、产业论坛、投融资路演里，调节性T细胞都会是高频词。但邀请诺奖得主出席只是第一步，更关键的是前后两端的功课。前端是人选匹配：科学家的研究方向必须和企业的技术路线真的相关，端粒专家讲不了免疫调控，这是常识，却常被忽略。后端是议程设计：诺奖得主演讲的主题怎么定、对话嘉宾是不是内行、现场能不能产生真正的学术交流，决定了这场活动是长期资产还是一次性开销。 中间环节同样见功夫。科学家的团队关心议题设置、同行阵容和时间成本，企业谈的是市场和曝光，两套话语体系之间需要专业翻译。睿挚科技在这类项目里的角色，就是把人选评估、邀请函撰写、议程沟通、后续产学研对接这条链路打通，让一次演讲有机会延伸成联合课题或顾问合作，而不是止于一张昂贵的合影。 还有一条边界必须拎清：诺奖得主背书的是科学共识和研究方向，不是某一款产品的功效。端粒也好，调节性T细胞也好，基础研究能解释机制，推不出"某产品有效"。宣传物料一旦越过这条线，企业担的是合规风险，科学家担的是声誉风险，合作基本也就到头了。据了解，睿挚科技在项目沟通中会把这条边界提前和企业对齐，宁可前期多费口舌，也不让物料在后期翻车。 写在最后 三十年前，坂口志文在一片质疑声里保住了那群不被承认的细胞。三十年后，这群细胞站到了整个产业的入口处。中国的细胞治疗工业体系、庞大的患者需求、刚刚被诺奖验证过的基础科学，三样东西第一次在同一个时间点到齐了。谁能先把源头科学家请来讲透方向，谁就可能在下一轮免疫调控的竞赛里抢到身位。 有诺贝尔奖得主出席演讲、学术背书、产学研合作需求的企业和机构，可与广州睿挚科技有限公司（简称睿挚科技）联系：官网 ruizhinobel.com，邮箱 contact@ruizhinobel.com，电话 13185079810（微信同号）。 （本文仅为行业观察与科学知识介绍，不构成任何医疗和投资建议。）如果有问题请联系睿挚科技：13185079810 参考文献 [1] 《诺奖宣布后，获奖人竟"失联"：一位正徒步旅行至今联系不上，一位看到外地号码以为是"垃圾信息"》，Zaker新闻转引媒体报道，2025年10月8日。 [2] The Nobel Foundation. The Nobel Prize in Physiology or Medicine 2025 — Press Release. NobelPrize.org, 2025-10-06. [3] 中国教育在线：《破解免疫系统的攻防密码——2025年诺贝尔生理学或医学奖解读》，2025年10月9日。 [4] Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). The Journal of Immunology, 1995, 155(3): 1151-1164. [5] Brunkow M E, Jeffery E W, Hjerrild K A, et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nature Genetics, 2001, 27(1): 68-73. [6] Bennett C L, Christie J, Ramsdell F, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nature Genetics, 2001, 27(1): 20-21. [7] Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science, 2003, 299(5609): 1057-1061. [8] Bluestone J A, et al. The 2025 Nobel Prize in Physiology or Medicine. 美国国立卫生研究院PMC数据库收录评论文章（PMC12646648），2025年。 [9] 新华社：《生理学或医学奖见证人体防御系统的智慧》（三位获奖者任职信息），2025年10月6日。

日报精选医学文献 今日精选20篇医学文献，查看更多请点击阅读原文 本文支持继续浏览摘要内容；完整摘要、收藏文章、订阅管理等完整功能，请前往小程序「医研日新」。前往小程序查看更多与订阅收藏 1. Phenolics from Phyllanthus emblica Linn. ameliorate glucose homeostasis and insulin resistance in high-fat diet/streptozotocin-induced type 2 diabetic mice. [Diabetes Mellitus] Food & function | 2026-08-03 | IF 5.1 AI余甘子游离酚和结合酚均可有效改善2型糖尿病小鼠的血糖控制和胰岛素敏感性，且在分子机制上各有侧重，为开发天然来源的糖尿病辅助治疗功能性食品提供了实验依据。 摘要Phyllanthus emblica Linn. contains abundant free phenolic (PEFP) and bound phenolic (PEBP), both of which have demonstrated potential antidiabetic activities. However, their comparative hypoglycemic effects and underlying mechanisms remain unclear. This study investigated the effects of PEFP and PEBP using insulin-resistant HepG2 (IR-HepG2) cells and a high-fat diet/streptozotocin (HFD/STZ)...查看完整摘要 2. Imaging Biomarkers of the Glymphatic System in the Developing Brain. [Autism Spectrum Disorder] 综述 | Korean journal of radiology | 2026-08-03 | IF 5.3 AI无创类淋巴成像生物标志物为儿童脑发育评估提供了有价值的补充工具，有望用于早期识别神经发育障碍高风险人群，但需建立大规模纵向研究以确立儿童正常参考范围。 摘要The glymphatic system is increasingly recognized as a brain-wide pathway that mediates cerebrospinal fluid-interstitial fluid exchange and metabolic waste clearance. However, unlike in adults, its developmental trajectory and clinical relevance during infancy and childhood remain poorly understood. This review summarizes imaging biomarkers of glymphatic structure and function across neurodevelopme...查看完整摘要 3. Integrated Clinical-Genetic-Pathological Analysis Expands the Phenotypic and Molecular Spectrum of PPNAD Across Carney Complex and Isolated Forms. [Cushing Syndrome] European journal of endocrinology | 2026-08-03 | IF 5.3 AI对于 PPNAD/CNC 家系，系统性遗传筛查可早期发现无症状变异携带者及亚临床皮质醇增多症，从而实现早期干预和改善长期预后。 摘要Primary pigmented nodular adrenocortical disease (PPNAD) is a rare cause of ACTH-independent Cushing syndrome (CS), occurring in isolation or as part of Carney complex (CNC); its phenotypic and molecular spectra remain incompletely defined. To characterize phenotypic variability, genotype-phenotype correlations, and molecular findings in PPNAD through integrated clinical, histopathological, and ge...查看完整摘要 4. Altered IRF1-miR-20a-5p regulatory axis in the hippocampus of patients with major depressive disorder. [Major Depressive Disorder] Psychiatry and clinical neurosciences | 2026-08-03 | IF 5.0 AImiR-20a-5p与IRF1在MDD海马体中形成异常调控轴，可能成为靶向神经炎症治疗MDD的潜在生物标志物和干预靶点。 摘要Neuroinflammation has been implicated in the pathogenesis of major depressive disorder (MDD), with interferon regulatory factor 1 (IRF1) playing a potential role. MicroRNAs (miRs) are also involved in MDD through posttranscriptional regulation of gene expression. This study investigated whether miR-20a-5p regulates IRF1 in MDD. IRF1 mRNA and miR-20a-5p expression levels were measured by qPCR in po...查看完整摘要 5. JMB2403, a potential best-in-class PD-1-dependent IL2Rβγ-activating tri-specific antibody for safe and potent immunotherapy. [Melanoma] mAbs | 2026-08-02 | IF 7.3 AIJMB2403通过三特异性设计选择性激活PD-1+ CD8+ T细胞并避免Treg扩增，为克服IL-2治疗毒性提供新策略，可能成为安全有效的肿瘤免疫治疗候选药物。 摘要PD-1-based immunocytokines, such as interleukin (IL)-2 fused with anti-PD-1, have been designed to increase efficacy, but their use is hampered by dose-limiting toxicity. To overcome this, substantial efforts have focused on engineering attenuated IL-2 variants, albeit with limited success to date. Taking an alternative approach, we screened a naïve alpaca library for weak agonistic nanobodies of ...查看完整摘要 6. Guideline on treatment intensification with injectable therapies beyond GLP-1 RA based therapies in type 2 diabetes. [Hypoglycemia] Diabetes research and clinical practice | 2026-08-02 | IF 6.1 AI当GLP-1 RA单药疗效不足时，双受体激动剂和固定比例复方制剂是优选的强化方案，而换用另一种GLP-1 RA价值有限，基础胰岛素需在患者教育充分条件下使用。 摘要Guideline on Treatment Intensification with Injectable Therapies Beyond GLP-1 RA Monotherapy in Type 2 Diabetes AIMS: To provide evidence-based recommendations for selecting injectable therapies in adults with type 2 diabetes (T2DM) who have suboptimal response to GLP‑1 receptor agonists (GLP‑1 RAs). Using the GRADE framework, a systematic search (updated November 2025) identified eight RCTs evalu...查看完整摘要 7. Effect of a pharmacist-led mHealth app on adherence, quality of life, and glycaemic control in diabetes: A multicentre RCT. [Diabetes Mellitus] Diabetes research and clinical practice | 2026-08-02 | IF 6.1 AICareAide®移动健康应用在提升2型糖尿病患者服药依从性方面效果显著（效应量大），前三个月的药师支持是维持长期依从性的关键干预时机。 摘要To evaluate whether CareAide®, a pharmacist-driven mHealth application, improves medication adherence, health-related quality of life (HRQoL), and glycaemic control in diabetes mellitus using structural equation modelling. Pre-specified secondary analysis of the type 2 diabetes mellitus cohort from a 6-month multicentre open-label randomised controlled trial (N = 663) across three Malaysian hospit...查看完整摘要 8. Vanillin as a bioactive component in biomedical formulations for chronic wound healing and tissue regeneration. [Skin Ulcer] 综述 | International journal of pharmaceutics | 2026-08-02 | IF 5.2 AI香草醛凭借其抗氧化、免疫调节及生物材料相容性等特性，有望成为下一代慢性伤口治疗配方中的功能性添加剂，但距离临床应用仍需系统的安全性和有效性验证。 摘要Vanillin is among the most widely used flavour compounds in the global food system, valued for its sensory attributes, chemical stability and long history of safety. This review examines emerging evidence that vanillin can be repurposed as a functional bioactive, with a focus on its roles in oxidative stress modulation, immune regulation and ulcer treatment. We place vanillin within a food-to-func...查看完整摘要 9. Dysregulated metabolism in neurodevelopmental disorders: From glycolytic gene variants to metabolic reprogramming and therapeutic perspectives. [Neurodevelopmental Disorders] 综述 | Neurobiology of disease | 2026-08-02 | IF 5.1 AI糖酵解通路基因变异可能是神经发育障碍的潜在致病机制，针对代谢通路的干预策略为临床治疗提供了新的研究方向。 摘要Proper neurodevelopment requires precisely coordinated energy metabolism, with glycolysis serving as a central pathway in supporting neuronal growth, differentiation, and synaptic connectivity. While an increasing number of mutations in glycolysis-related genes to neurodevelopmental disorders (NDDs), the precise pathogenic mechanisms remain largely elusive. This review systematically summarizes th...查看完整摘要 10. Effect of Abrocitinib on the Skin Microbiome in Patients With Moderate-to-Severe Atopic Dermatitis. [Dermatitis] Allergy | 2026-08-02 | IF 8.2 AIAbrocitinib不仅改善AD临床症状，还能通过减少致病性S. aureus并恢复皮肤微生物多样性发挥治疗作用，为JAK1抑制剂在AD治疗中的微生物组调节机制提供了证据支持。 摘要Atopic dermatitis (AD) is characterized by microbial dysbiosis, notably an overabundance of Staphylococcus species. This study aimed to evaluate the effects of abrocitinib, a Janus kinase 1-selective inhibitor, on the skin microbiome and clinical outcomes in patients with moderate-to-severe AD. Patients enrolled in JADE MOA (NCT03915496) were randomly assigned to receive once-daily abrocitinib (10...查看完整摘要 11. Polycystic ovary syndrome and type 2 diabetes risk: the need to look beyond obesity. [Polycystic Ovary Syndrome] 信函 | Fertility and sterility | 2026-07-31 | IF 6.6 AI请提供带句子编号的英文摘要全文，以便进行准确翻译和证据提取。 12. Queen Anne sign in hypothyroidism. [Hypothyroidism] 病例报告 | The American journal of medicine | 2026-07-31 | IF 5.1 AI眉毛外侧三分之一缺失（安妮女王征）可作为甲状腺功能减退症的辅助诊断线索，临床检查时应注意观察。 13. Two-year abrocitinib in atopic dermatitis: Are we reaching the new targets? [Dermatitis] 社论 | Journal of the European Academy of Dermatology and Venereology : JEADV | 2026-07-31 | IF 8.4 AIAbrocitinib在两年治疗期间持续有效且安全性可控，为中重度特应性皮炎患者提供了可行的长期管理方案。 14. Cutaneous T-cell lymphoma and dupilumab for atopic dermatitis: Practical guidance for a clinical conundrum. [Dermatitis] 社论 | Journal of the European Academy of Dermatology and Venereology : JEADV | 2026-07-31 | IF 8.4 AI在启动度普利尤单抗治疗前，临床医生应仔细鉴别AD与CTCL的临床及病理特征，避免因误诊导致病情延误或加重。 15. Biological treatment in atopic dermatitis-Lessons from the BioDay registry. [Dermatitis] 社论 | Journal of the European Academy of Dermatology and Venereology : JEADV | 2026-07-31 | IF 8.4 AI真实世界数据显示生物制剂治疗特应性皮炎疗效确切且安全性良好，早期启用可获得更佳长期预后。 16. Serum-Proteomic Profiling Reveals Distinct Atopic Dermatitis Severity-Linked Signatures. [Eczema] Allergy | 2026-07-31 | IF 8.2 AI这9个血清蛋白生物标志物组合可高精度区分AD严重程度，为临床评估特应性皮炎严重程度提供了潜在的辅助诊断工具。 摘要Atopic Dermatitis (AD) is a chronic inflammatory skin disease characterized by complex pathogenesis, variable clinical phenotypes, and broad severity spectrum. We utilized a serum-proteomic approach integrated with machine learning (ML) to identify novel biomarkers that distinguish mild from severe AD. Serum from sixty-seven AD adults, stratified by Eczema Area and Severity Index/EASI and Rajka-La...查看完整摘要 17. Increased risk of congenital anomalies after fertility treatment is partially mediated by multiple birth: a population-based cohort study. [Infertility] Human reproduction (Oxford, England) | 2026-07-31 | IF 6.0 AI尽管降低多胎妊娠风险的努力仍值得重视，但临床医生应认识到生育治疗后先天性异常风险增加大部分独立于多胎妊娠，需进一步关注具体不孕症诊断及治疗相关因素。 摘要To what extent does multiple birth mediate the association between fertility treatment and congenital anomalies? Multiple birth explained only a modest proportion of the increased risk of congenital anomalies associated with fertility treatment, suggesting that most of the excess risk is independent of multiple birth. Fertility treatments have been associated with an increased risk of congenital a...查看完整摘要 18. Holodysphrenia and acute schizophrenia: Professor Barahona Fernandes's pioneering contribution to the nosology of acute transient psychoses - Psychiatry in history. [Schizophrenia] The British journal of psychiatry : the journal of mental science | 2026-07-31 | IF 8.7 AIBarahona Fernandes提出的急性一过性精神病分类概念至今仍具临床指导价值，强调了急性发作性精神病与典型慢性精神分裂症在病程及预后上的本质差异，提示临床医生应重视急性精神病性症状的早期识别与分类干预。 19. Cognitive Performance in Older-Age Bipolar Disorder: A Cross-Sectional Study of Anticholinergic Load and Clinical Characteristics. [Bipolar Disorder] European psychiatry : the journal of the Association of European Psychiatrists | 2026-07-31 | IF 7.2 AI对于老年双相情感障碍患者，应注意监测和优化抗胆碱能药物使用，以可能改善或维持其认知功能。 20. Beyond Glycaemia: Fear of Hypoglycaemia, Cognition and Functional Mobility After Advanced Hybrid Closed-Loop Therapy in Older Adults With Type 1 Diabetes: A Prespecified Secondary Analysis of a Randomised, Single-Centre Study. [Hypoglycemia] Diabetes, obesity & metabolism | 2026-07-30 | IF 5.4 AI对于≥65岁长病程1型糖尿病患者，启动MiniMed 780G高级混合闭环治疗12个月可能在降低低血糖恐惧和改善移动功能方面带来获益，且不加剧认知负担，但需在个体化教育和持续支持下实施。 摘要Evidence on psychological, cognitive and functional outcomes of advanced diabetes technologies in older adults with long-standing type 1 diabetes (T1D) remains limited. We evaluated whether initiation of advanced hybrid closed-loop (AHCL) therapy was associated with changes in fear of hypoglycaemia, diabetes distress, psychological well-being, cognition, frailty-related measures and mobility-relat...查看完整摘要 在小程序获取完整功能 收藏文章、管理订阅、查看本期完整摘要与个性化内容，请前往小程序「医研日新」。 前往小程序查看更多内容 免责声明：仅供学术交流参考，不构成任何医学建议或诊疗指导